Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006-10-01
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
Related Questions
For either patients in general or for patients who will receive regimens with well-described toxicities such as irinotecan/UGT1A1.
If so, do you requ...
New comment by Medical Oncologist at Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center ( January 13, 2025)
It is worth noting that the great majority of fatal toxicities related to DPD deficiency occur in patients with a single deleterious DPYD gene mutation; "double DPYD mutations...